Get the Daily Brief
Latest Biotech News
Contineum’s J&J‑partnered MS drug misses endpoints; company re‑examines data
Contineum Therapeutics reported that PIPE‑307, an oral M1 receptor antagonist developed with Janssen, failed to meet its primary efficacy endpoint in a Phase 2 VISTA trial in relapsing‑remitting...
Nurix trims staff as pivotal BTK degrader DAYBreak trial kicks off
Nurix Therapeutics announced a targeted workforce reduction while initiating the DAYBreak pivotal Phase 2 trial of its oral BTK degrader bexobrutideg in relapsed or refractory chronic lymphocytic...
Ensoma halves workforce after shifting from platform to clinic
Ensoma disclosed a roughly 50% reduction in headcount as it transitions from platform development toward clinical execution, focusing resources on its lead clinical candidate EN‑374 for X‑linked...
Cassidy Bio raises $8M to build AI platform for gene‑editing design
Tel Aviv‑based Cassidy Bio closed an $8 million seed round to develop an AI platform that predicts optimal combinations of guide RNAs, editing enzymes and delivery modalities for therapeutic...
Profluent closes $106M to scale AI protein design and commercialization
Profluent raised $106 million in a financing led by Altimeter Capital and Bezos Expeditions to expand its large‑scale AI models for protein design. The Emeryville company will use the funds to...
Broad’s prime‑editing trick: one agent to rescue many genetic disorders
Researchers in David Liu’s lab at the Broad Institute described a prime‑editing strategy—termed PERT—that installs suppressor tRNAs via prime editing to rescue premature termination codons across...
Moderna secures $1.5B while pruning pipeline to sharpen focus
Moderna announced a $1.5 billion financing to support its plans to expand an expected seasonal vaccine franchise and to fund investments in oncology and rare disease programs as it targets...
Function Health’s $298M Series B: lab testing startup hits unicorn mark
Function Health raised $298 million in a Series B round led by Redpoint Ventures, pushing its valuation to about $2.5 billion. The Austin‑based company offers consumer‑facing access to an expanded...
Abbott to buy Exact Sciences: $21B deal reshapes cancer diagnostics
Abbott agreed to acquire Exact Sciences in an all-cash transaction that values the cancer‑testing company at roughly $21 billion (about $23 billion enterprise value), according to company filings...
Pfizer’s mRNA flu shot... shows 34.5% efficacy edge in phase 3
Pfizer released full phase 3 data showing its mRNA seasonal influenza vaccine candidate delivered 34.5% greater efficacy than a standard control vaccine in the pivotal study. The readout expands...
Bayer’s Hyrnuo wins FDA nod — companion CDx cleared by Thermo Fisher
The U.S. FDA granted approval to Bayer’s oral HER2‑directed kinase inhibitor Hyrnuo (sevabertinib) for adults with advanced HER2‑mutant non‑small‑cell lung cancer, and Thermo Fisher’s Ion Torrent...
Contineum’s J&J‑partnered MS drug flops in mid‑stage test — misses primary goals
Contineum Therapeutics reported that PIPE‑307, an oral M1 receptor antagonist developed with Janssen (J&J), failed to meet its primary efficacy endpoint in the Phase 2 VISTA trial for...
Moderna secures $1.5B lifeline — prunes pipeline to focus on seasonal vaccines and oncology
Moderna said it had secured $1.5 billion in financing to underpin operations as it pursues break‑even targets in 2028 and pivots investment toward an expanded seasonal vaccine franchise and...
Function Health raises $298M — lab‑testing startup hits $2.5B valuation
Function Health closed a $298 million Series B led by Redpoint Ventures, lifting the lab‑testing startup’s valuation to about $2.5 billion. The company offers subscription access to a broad menu...
Profluent nets $106M to scale AI protein design — Bezos, Altimeter join round
Profluent closed a $106 million financing led by Altimeter Capital and Bezos Expeditions to accelerate large‑scale AI models for protein design, the company said. Profluent will expand its...
Cassidy Bio raises $8M seed to AI‑drive gene‑editing design platform
Tel Aviv‑based Cassidy Bio closed an $8 million seed round led by Ahren Innovation Capital to develop an AI platform that predicts optimal combinations of guide RNAs, enzymes and delivery...
GSK taps Flagship platforms: Profound and Quotient get first projects
GSK and Flagship Pioneering revealed the first company‑specific deals under their multi‑platform collaboration: Profound Therapeutics will apply its ProFoundry proteomics platform and Quotient...
Tessera to begin first human gene‑writing trial — genomic AI designs follow
Tessera Therapeutics confirmed an imminent start to its first‑in‑human trial of an in‑vivo gene‑writing platform, enrolling adults with a rare genetic disease. The move marks a key inflection...
Abbott buys Exact Sciences: $23B bet on cancer diagnostics
Abbott announced a definitive agreement to acquire Exact Sciences in a cash deal valued at roughly $21–23 billion, paying $105 per share and folding Exact’s cancer‑screening portfolio into...
Bayer’s HER2 pill cleared: FDA greenlights Hyrnuo for lung cancer
The U.S. Food and Drug Administration granted approval to Bayer’s oral HER2‑directed therapy Hyrnuo (sevabertinib) for adults with locally advanced or metastatic non‑squamous NSCLC harboring...